Tuesday, December 15, 2015 - Thursday, December 15, 2016 12:00 AM
At the conclusion of this activity, participants should be able to:
- Discuss the application of precision medicine to the management of advanced malignancies.
- Explain why cancer is a logical first choice for evaluating the impact of precision medicine.
- Discuss the potential limitations of treatment focused on inactivating a single oncogene.
- Summarize the major efforts underway to collect additional evidence supporting the benefits of a precision medicine-based approach for guiding cancer treatment.
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
The planning committee and those in a position to control the content of this activity have disclosed no relevant financial relationships.